Literature DB >> 10474521

Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.

J H Lagendijk1, H Mullink, P J van Diest, G A Meijer, C J Meijer.   

Abstract

AIM: To discriminate between adenocarcinomas that are primary to the ovary and metastatic to the ovary, especially of colonic and breast origin, by immunohistochemistry, using stepwise discriminant analysis or a decision tree.
METHODS: 312 routinely processed, formalin fixed tissue specimens were used. The tumours were divided into a learning set (n = 159), composed of primary tumours of ovary, breast, and colon, and a test set, comprising 134 metastases from these sites and an additional 19 primary ovarian carcinomas. The immunohistochemical panel was composed of antibodies against cytokeratin 7 (CK7) and 20 (CK20), CA125, vimentin, carcinoembryonic antigen (CEA), gross cystic disease fluid protein-15 (GCDFP-15), and the oestrogen receptor (ER). The staining results of the tumours were expressed as the product of the staining intensity and the percentage of positive tumour cells. Analyses were first performed on the learning set and then evaluated on the test set.
RESULTS: Although the immunostaining patterns showed a considerable overlap between the three types of adenocarcinoma, the breast carcinomas were typically positive for GCDFP-15 and often for ER, and negative for vimentin. Ovarian carcinomas were always positive for CK7 and to a lesser extent for CA125. Colonic carcinomas showed prominent positivity for CEA and CK20, while no staining was seen for ER and vimentin. In discriminant analysis, six antibodies (alpha CK7, alpha CK20, alpha CA125, alpha CEA, alpha ER, and alpha GCDFP-15) appeared to be necessary for optimal classification: 89% of the learning set and 82% of the test set were classified correctly. In the decision tree, only four antibodies (alpha CK7, alpha CEA, alpha ER, and alpha GCDFP-15) were used to obtain a correct classification score of 89% for the learning set and 84% for the test set.
CONCLUSIONS: Using a semiquantitative assessment of the immunostaining results by a restricted panel of six antibodies with stepwise discriminant analysis, 80-90% of the adenocarcinomas of colon, breast, and ovary can be correctly classified. Discriminant analysis is computer aided and therefore an easy method and for each case a probability value of the classification result is obtained. The intuitive decision tree method provides a slightly better result, requires only four antibodies, and offers a more practical method for the surgical pathologist.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474521      PMCID: PMC501334          DOI: 10.1136/jcp.52.4.283

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  32 in total

1.  Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.

Authors:  J H Lagendijk; H Mullink; P J Van Diest; G A Meijer; C J Meijer
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

2.  Cancer metastatic to the ovary: factors influencing survival.

Authors:  M J Webb; D G Decker; E Mussey
Journal:  Obstet Gynecol       Date:  1975-04       Impact factor: 7.661

3.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

4.  Secondary ovarian neoplasia. A clinicopathologic study of 35 cases.

Authors:  T M Ulbright; L M Roth; F B Stehman
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

5.  Intestinal adenocarcinomas metastatic to the ovaries. A clinicopathologic evaluation of 22 cases.

Authors:  R H Lash; W R Hart
Journal:  Am J Surg Pathol       Date:  1987-02       Impact factor: 6.394

6.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

7.  Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases.

Authors:  G Viale; M Gambacorta; P Dell'Orto; G Coggi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry.

Authors:  H J Helin; M J Helle; O P Kallioniemi; J J Isola
Journal:  Cancer       Date:  1989-05-01       Impact factor: 6.860

9.  Use of statistical evaluation of antigen profiles in differential diagnosis between colonic and ovarian adenocarcinomas.

Authors:  S C Henzen-Logmans; N W Schipper; L G Poels; K Stolk; P Kenemans; C J Meyer
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

10.  Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors.

Authors:  G Mazoujian; C Bodian; D E Haagensen; C D Haagensen
Journal:  Cancer       Date:  1989-06-01       Impact factor: 6.860

View more
  23 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  [Breast metastases].

Authors:  Dolores Arribas del Amo; M Pilar Santero Ramírez; Elena Córdoba Díaz de Laspra; Fernando Martínez Ubieto; Mónica Corral Subías; Alfonso Cay Diarte
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

Review 3.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

4.  Morphological effects of chemotherapy on ovarian carcinoma.

Authors:  W G McCluggage; R W Lyness; R J Atkinson; S P Dobbs; I Harley; H R McClelland; J H Price
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

Review 5.  Microarray techniques in pathology: tool or toy?

Authors:  A M Snijders; G A Meijer; R H Brakenhoff; A J van den Brule; P J van Diest
Journal:  Mol Pathol       Date:  2000-12

Review 6.  Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Authors:  John D Hainsworth; F Anthony Greco
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.

Authors:  Mirte M Streppel; Audrey Vincent; Radha Mukherjee; Nathaniel R Campbell; Shih-Hsun Chen; Konstantinos Konstantopoulos; Michael G Goggins; Isabelle Van Seuningen; Anirban Maitra; Elizabeth A Montgomery
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

8.  The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.

Authors:  Mi Jin Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

9.  Comparative genomic hybridisation as a supportive tool in diagnostic pathology.

Authors:  M M Weiss; E J Kuipers; S G M Meuwissen; P J van Diest; G A Meijer
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 10.  Isolated splenic metastasis of ovaric cancer. Case report and literature review.

Authors:  G Resta; L Vedana; Silvia Marino; L Scagliarini; M Bandi; G Anania
Journal:  G Chir       Date:  2014 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.